Bio-Connect

Anti-CD22 [hL22 (Epratuzumab)]

Research Use Only
Ab00728-35.0
Absolute Antibody
ApplicationsFlow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman, Monkey, Primate
TargetCD22
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-CD22 [hL22 (Epratuzumab)]
  • Delivery Days Customer
    7
  • Antibody Specificity
    This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
  • Application Supplier Note
    Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
  • Applications
    Flow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking
  • Applications Supplier
    Blocking; IP; FC
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    hL22 (Epratuzumab)
  • Gene ID933
  • Target name
    CD22
  • Target description
    CD22 molecule
  • Target synonyms
    B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigen; sialic acid-binding Ig-like lectin 2; SIGLEC2; SIGLEC-2; T-cell surface antigen Leu-14
  • Host
    Monkey
  • Isotype
    IgG1
  • Protein IDP20273
  • Protein Name
    B-cell receptor CD22
  • Scientific Description
    This chimeric cynomolgus monkey antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
  • Reactivity
    Human, Monkey, Primate
  • Reactivity Supplier
    Human, Rhesus Monkey, Cynomolgus Monkey
  • Reactivity Supplier Note
    This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203